simvastatin has been researched along with Maxillary Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haycraft, CJ; Huang, Y; Jin, J; Kirkwood, KL; Li, Q; Li, Y; Lopes-Virella, MF; Lu, Z; Yu, H; Zhang, X | 1 |
| Le, HO; Marx, DB; Narayana, N; Powell, SE; Price, U; Reinhardt, RA; Schmid, MJ; Wang, D; Zhang, Y | 1 |
2 other study(ies) available for simvastatin and Maxillary Diseases
| Article | Year |
|---|---|
Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease.
Topics: Acid Phosphatase; Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Gingiva; Gingivitis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Isoenzymes; Lipopolysaccharides; Matrix Metalloproteinase 9; Maxillary Diseases; Osteoclasts; Periodontal Diseases; Rats; Rats, Sprague-Dawley; Simvastatin; Tartrate-Resistant Acid Phosphatase; Toll-Like Receptors; X-Ray Microtomography | 2014 |
Effects of local simvastatin-alendronate conjugate in preventing periodontitis bone loss.
Topics: Alendronate; Alveolar Bone Loss; Animals; beta-Cyclodextrins; Bone Density Conservation Agents; Drug Combinations; Endotoxins; Escherichia coli; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imaging, Three-Dimensional; Injections; Lipopolysaccharides; Maxillary Diseases; Molar; Osteoclasts; Palate; Periodontitis; Premedication; Rats; Rats, Sprague-Dawley; Sequestering Agents; Simvastatin; X-Ray Microtomography | 2013 |